Targeting CLDN6 in germ cell tumors by  an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options

CONCLUSIONS: In summary, this study offers a novel CLDN6-ADC to target GCT. Additionally, this study presents novel pharmacological inhibitors blocking FGF, VGF, PDGF, mTOR, CHEK1, AURKA, or PARP signaling for the treatment of (refractory) YST patients. Finally, this study shed light on the mechanisms of therapy resistance in YST.PMID:36991316 | DOI:10.1186/s10020-023-00636-3

Source: Molecular Medicine - March 29, 2023 Category: Molecular Biology Authors: Margaretha A Skowron Mara Kotthoff Felix Bremmer Katja Ruhnke Fatma Parmaksiz Annika Richter Stefan K üffer Kirsten Reuter-Jessen Stella Pauls Anja Stefanski Philipp Str öbel Kai St ühler Daniel Nettersheim Source Type: research